Topiramate add-on for drug-resistant partial epilepsy
Authors:
- Nathalie JetteNJNathalie Jette
- Karla HemmingKHKarla Hemming
- Jane L HuttonJHJane L Hutton
- Anthony G MarsonAMAnthony G Marson
- 16 July 2008
- reference entry
- Published by Wiley
- No. 3,p. CD001417
Abstract
The majority of people with epilepsy have a good prognosis and their seizures are controlled by a single antiepileptic drug. However, up to 20% of patients from population-based studies and up to 30% from clinical series (not population-based) develop drug-resistant epilepsy, especially those with partial onset seizures. In this review we summarize the current evidence regarding a new antiepileptic drug, topiramate, when used as an add-on treatment for drug-resistant partial epilepsy. To evaluate the efficacy and safety of topiramate when used as an add-on treatment for drug-resistant partial epilepsy. We searched the Cochrane Epilepsy Group Specialized Register (10 May 2007); the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 3, 2007). No language restrictions were imposed. We also contacted the manufacturers of topiramate and researchers in the field to see any ongoing or published studies. Randomized placebo controlled add-on trials of topiramate recruiting people with drug-resistant partial epilepsy. Two review authors independently selected trials for inclusion and extracted the relevant data. The following outcomes were assessed: (a) 50% or greater reduction in seizure frequency; (b) treatment withdrawal (any reason); (c) side effects. Primary analyses were intention-to-treat. Summary relative risks (RR) with 95% confidence intervals (95% CI) are presented. Dose response was evaluated in regression models. Ten trials were included representing 1312 randomized participants. Baseline phases ranged from 4-12 weeks and double-blind phases from 11-19 weeks. The RR for a 50% or greater reduction in seizure frequency compared to placebo was 2.85 (95% CI 2.27 to 3.59). Dose regression analysis shows increasing effect with increasing dose, but found no advantage for doses over 300 or 400 mg per day. The RR for treatment withdrawal compared to placebo was 2.26 (95% CI 1.55 to 3.31). The RR for the following side effects indicate that they are significantly associated with topiramate: ataxia 1.95 (99% CI 1.04 to 3.65); dizziness 1.55 (99% CI 1.08 to 2.22); fatigue 2.19 (99% CI 1.43 to 3.35); nausea 2.35 (99% CI 1.28 to 4.29); somnolence 2.18 (99% CI 1.47 to 3.21) and 'thinking abnormally' 5.77 (99% CI 2.50 to 13.35). Topiramate has efficacy as an add-on treatment for drug-resistant partial epilepsy. However, trials reviewed were of relatively short duration, and provide no evidence for the long-term efficacy of topiramate. Results cannot be extrapolated to monotherapy or treating other epilepsy types.Keywords
This publication has 21 references indexed in Scilit:
- The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trialThe Lancet, 2007
- Low-dose topiramate in adults with treatment-resistant partial-onset seizuresActa Neurologica Scandinavica, 2002
- Clinical effects of topiramate against secondarily generalized tonic–clonic seizuresEpilepsy Research, 2002
- A Multicenter, Randomized Clinical Study to Evaluate the Effect on Cognitive Function of Topiramate Compared with Valproate as Add‐On Therapy to Carbamazepine in Patients with Partial‐Onset SeizuresEpilepsia, 2000
- Effectiveness, Tolerability, and Safety of Topiramate in Children with Partial‐Onset SeizuresEpilepsia, 2000
- Topiramate in Medically Intractable Partial Epilepsies: Double‐Blind Placebo‐Controlled Randomized Parallel Group TrialEpilepsia, 1999
- Double‐Blind, Placebo‐Controlled Trial of Topiramate (600 mg Daily) for the Treatment of Refractory Partial EpilepsyEpilepsia, 1996
- Remission of epilepsy: results from the National General Practice Study of EpilepsyThe Lancet, 1995
- Phenytoin Monotherapy for Epilepsy: A Long‐Term Prospective Study, Assisted by Serum Level Monitoring, in Previously Untreated PatientsEpilepsia, 1981
- The Epidemiology of Epilepsy in Rochester, Minnesota, 1935 Through 1967Epilepsia, 1975